Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2008-06-24
2008-06-24
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S152100, C424S172100, C424S184100, C424S810000, C530S388220, C530S388230, C530S388250, C530S389200, C530S389300, C530S389600
Reexamination Certificate
active
07390490
ABSTRACT:
There are provided uses of an antibody directed to CX3CR1 and fractalkine. Killer lymphocytes can be readily identified, eliminated and separated by using an anti-CX3CR1 antibody. Further, there can be provided an antibody drug for suppressing chemotaxis and cytotoxic activity of killer lymphocytes by suppressing an interaction between CX3CR1 and fractalkine.
REFERENCES:
patent: 6013257 (2000-01-01), Pan
patent: 2001-218581 (2001-08-01), None
Dorland's Illustrated Medical Dictionary, 27thEdition [1988]. Taylor et al, eds., W.B Saunder Co, Philadelphia, PA, pp. 1089 and 1460.
Ruth et al. Arthritis & Rheumatism [Jul. 2001] 44(7):1568-1581.
Wong et al. Cardiovascular Pathology [2002] 11:332-338.
T. Imai et al., “Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, which Mediates Both Leucokyte Migration and Adhesion”,Cell, 91: 521-530, Nov. 14, 1997.
L. Feng et al., “Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1. Rapid Communication”,Kidney International, 56: 612-620, 1999.
Proceedings of the Japanese Society for Immunology, 30: p. 192, 2-F-270-P/O, 2000.
D.M. Hoover et al., “The Crystal Structure of the Chemokine Domain of Fractalkine Shows a Novel Quaternary Arrangement”,J. Biol. Chem., 275: 23187-23193, 2000.
A.D. Lucas et al., “The Transmembrane Form of the CXCL1 Chemokine Fractalkine is Expressed Predominantly by Epithelial Cells in Vivo”,Am. J. Pathol., 158: 855-866, 2001.
A. Campbell et al., “General Properties and Applications on Monoclonal Antibodies” in Monoclonal Antibody Technology, 1985, pp. 1-32.
J.K. Harrison et al., “Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia”, Proc. Natl. Acad. Sci. USA, 1998, 95: 10896-10901.
Notice of Reason for Rejection mailed on Dec. 12, 2006 in corresponding Japanese application No. 2001-308619 (and corresponding English Translation).
O. Yoneda et al., “Effects of Fractalkine on NK cell activity and NK cell-mediated damage of endothelial cells”,J. Osaka Odontol. Soc.,1999, 62(2): 90-97 (and English translation of abstract).
O. Yoneda et al., “Fractalkine-mediated endothelial cell injury by NK cells”,J. Immunol.,2000, 164: 4055-4062.
Verified Translation of Japanese patent application No. JP 2001-077384.
Imai Toshio
Kuboi Yoshikazu
Muramoto Kenzo
Nishimura Miyuki
Chan Christina
Choate Hall & Stewart LLP
Eisai Co. Ltd.
Herschbach Jarrell Brenda
VanderVegt F. Pierre
LandOfFree
Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2802309